Test Directory

MRD monitoring BCR::ABL1 E1A2 transcript

Containers - Adult

RedCapTubeEDTAKE9ml.jpg
Red Cap Tube EDTA KE 9ml
Volume Range

​10-15ml peripheral blood or bone marrow specimen
Additive per Container

EDTA

Laboratory Site

WGH
Crewe Road South
Edinburgh
EH4 2XU
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  Specimens should arrive no later than 3.30pm on Friday.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road

Edinburgh

EH4 2XU​

 

See also Specimen transportation.

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

​Requests may be made using our request form or via TRAK.  Please refer to our detailed requesting ​instructions.  The HMDS request form can be located here.​

 

HMDS request form PDF_v5.pdf

Availability

​Monday-Friday 9am-5pm

Anticipated turnaround

Results should be expected within 10 working days.  See results.

What happens if the result is positive or abnormal

​The requesting clinician will be contacted where results are clinically significant. Please ensure details are included on request form. 

Static information/disclaimer

This test is accredited to ISO 15189:2012

General additional information

This test is MRD monitoring for patients with the BCR::ABL1 E1A2 [p190] transcript only.

For patients with BCR::ABL1 E13A2/E14A2 [p210] transcripts please see MRD monitoring for BCR::ABL1 E13A2/E14A2 quantification.

For suspected CML samples refer to BCR::ABL1 diagnostic and for AML and ALL diagnostic samples refer to AML and ALL panel testing respectively

This assay is performed to quantify BCR::ABL1 E1A2 [p190] transcripts in patients known to carry this specific fusion transcript.  It is not suitable for the quantification of other variant transcripts (e.g. E6A2, E19A2).

Monitoring of the level of BCR::ABL1 fusion transcript is vital for the assessment of response to tyrosine kinase inhibitor therapy and the early identification of therapy resistance. In contrast to E13A2/E14A2 fusion transcripts, no international scale is available for E1A2 fusion transcripts.

For clinical advice on appropriate investigations and advice for the interpretation of test results, please see contact us​.